• Cefiderocol’s In Vitro Efficacy Against Resistant Enterobact

  2026-05-26

  Santerre Henriksen et al. present a pivotal analysis of cefiderocol’s in vitro activity against a broad cohort of European Enterobacterales, including isolates resistant to both meropenem and recently approved β-lactam/β-lactamase inhibitor combinations. The findings highlight cefiderocol’s superior or comparable efficacy, offering critical guidance for antimicrobial stewardship and future research on multidrug-resistant Gram-negative infections.

• WAY-100635: Unraveling 5-HT1A Antagonism in Pain and Emotion

  2026-05-26

  Explore HOW WAY-100635, a potent serotonin 5-HT1A antagonist, enables advanced neuroscience research on pain and emotion. This article goes beyond standard guides to dissect assay design, translational opportunities, and protocol refinements anchored in recent mechanistic findings.

• KR-12 Human Antimicrobial Peptide: Applied Research Workflow

  2026-05-25

  KR-12 (human) TFA is the minimal, potent fragment of LL-37, uniquely combining antimicrobial, anti-biofilm, and immunomodulatory properties with proven efficacy in preclinical models. This article details actionable protocols, troubleshooting strategies, and translational insights for deploying KR-12 in advanced infection, inflammation, and gut microbiome studies.

• Escitalopram in Translational Psychiatry: Mechanistic and St

  2026-05-25

  Explore the mechanistic precision and strategic value of Escitalopram (Lexapro) for translational neuroscience research. This article provides actionable guidance for leveraging high-purity Escitalopram from APExBIO in advanced antidepressant and anxiolytic models, integrating protocol advances, critical findings from augmentation trials, and a forward-looking perspective on serotonergic pathway research.

• Adefovir (GS-0393): Structural Selectivity and Advanced HBV

  2026-05-24

  Discover how Adefovir (GS-0393) achieves potent, selective inhibition of hepatitis B virus polymerase. This article offers a deep dive into the structural and mechanistic underpinnings that set Adefovir apart for advanced HBV research applications.

• High-Throughput BBB Model: Predicting CNS Drug Permeability

  2026-05-23

  The reference study introduces a robust, high-throughput in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells, enhancing the prediction of CNS drug permeability. By integrating lysosomal trapping correction, the model improves alignment with in vivo brain distribution, streamlining early-stage screening for brain-penetrant compounds.

• Thiothixene: Dual Antipsychotic and Efferocytosis Modulator

  2026-05-22

  Explore how Thiothixene, a typical antipsychotic agent, uniquely enhances macrophage efferocytosis in addition to its psychiatric applications. This article delves into breakthrough mechanistic insights and advanced assay guidance not covered in prior literature.

• Cisapride (R 51619): Deep Dive into Cardiotoxicity Modeling

  2026-05-22

  Explore how Cisapride (R 51619) advances cardiac electrophysiology research by enabling high-content, deep learning–driven detection of arrhythmia risk. This article uniquely links molecular pharmacology to next-generation phenotypic screening strategies.

• Placebo-Controlled Evidence for Mianserin HCl in Depression

  2026-05-21

  A rigorous double-blind, placebo-controlled trial established the antidepressant efficacy of Mianserin Hydrochloride in hospitalized women with severe depression. The study highlights significant improvements in both mood and sleep quality, supporting Mianserin HCl's role as a 5-HT2 receptor antagonist in psychiatric research.

• 5-HT3 Antagonists Inhibit Renal OCT2 and MATE1: Insights for

  2026-05-21

  George et al. systematically evaluated how five clinically relevant 5-HT3 receptor antagonists inhibit renal drug transporters OCT2 and MATE1 using in vitro kidney cell models. Their findings clarify the variable inhibitory potency among these agents, revealing implications for drug interaction research and transporter-targeted experimental workflows.

• Vacuolin-1: A Precision Lysosomal Exocytosis Inhibitor for C

  2026-05-20

  Vacuolin-1 empowers membrane trafficking and plasma membrane repair research with unparalleled selectivity for lysosomal exocytosis inhibition. This guide details optimized protocols, data-driven troubleshooting, and advanced use-cases that leverage Vacuolin-1's unique properties for robust and reproducible cellular assays.

• Escitalopram Applications in Antidepressant Research Workflo

  2026-05-20

  Discover how Escitalopram from APExBIO enables high-fidelity antidepressant and anxiolytic activity assays with unmatched selectivity for serotonergic signaling. This guide delivers workflow blueprints, troubleshooting insights, and practical optimizations for reliable, reproducible results.

• Chicken ANP32A Redundancy Governs Avian Influenza Polymerase

  2026-05-19

  This study reveals that chicken ANP32A supports avian influenza polymerase through three partially redundant mechanisms: a SUMO-interacting motif, specific SUMOylation sites, and a unique avian-specific insertion. The findings clarify the species barrier at the molecular level and suggest new directions for host adaptation research.

• Perospirone (SM-9018 Freebase): Advanced Use in Schizophreni

  2026-05-19

  Perospirone (SM-9018 freebase) enables researchers to dissect serotonergic, dopaminergic, and vascular pathways in schizophrenia and cardiovascular models with precision. Its proven dual action—classic receptor antagonism and selective Kv1.5 channel inhibition—offers an experimental edge for both neuropsychiatric and vascular pharmacology studies.

• Lamotrigine: High-Purity Sodium Channel Blocker for CNS Rese

  2026-05-18

  Lamotrigine, chemically 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, is a rigorously characterized anticonvulsant compound used in neurological and cardiac research. It acts as a sodium channel blocker and serotonin pathway inhibitor, with well-documented IC50 values and exceptional purity. This article details its mechanistic rationale, validated benchmarks, and integration in state-of-the-art blood-brain barrier models.

7928 records 14/529 page Previous Next First page 上5页 1112131415 下5页 Last page